DENV-4
Overview
DENV-4 is one of the four dengue virus serotypes (DENV-1 through DENV-4). It caused the 2006 Cuban epidemic — the first DENV-4 outbreak in Cuba — following prior epidemics of DENV-1 (1977), DENV-2 (1981), and DENV-3 (2001). This serial introduction of serotypes means many Cuban adults infected in 2006 were experiencing a secondary, tertiary, or quaternary dengue infection.
Key Points from Literature
- The 2006 Cuban DENV-4 epidemic provided a cohort of hospitalized adults with known prior infection sequences, enabling follow-up studies on sequelae, immunological correlates, and genetic risk factors (see Garcia2009 - Long-term Clinical Symptoms Post-Dengue, Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism).
- Among a symptomatic subset followed 2 years post-infection, 12/26 had tetravalent infection history (DENV-1→2→3→4); only 5/26 were experiencing primary DENV-4 infection. Accumulating infection history may be a trigger for post-dengue autoimmunity (see Garcia2009 - Long-term Clinical Symptoms Post-Dengue).
- The same 2006 DENV-4 cohort (97 symptomatic + 42 asymptomatic) was used to show FcγRIIa-HH as a strong risk factor for symptomatic disease (DF and DHF) vs asymptomatic infection, and RR as protective (see Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism).
DENV-4 in the Cuban serial serotype introduction pattern
Guzman2016 describes DENV-4’s introduction as part of the larger pattern of sequential serotype introductions into Cuba — a country with strong vector control and no endemic dengue between epidemics. The sequence was: DENV-1 (1977) → DENV-2 Asian genotype (1981) → DENV-3 Asian genotype (2001) → DENV-4 (2006). Notably, the DENV-4 epidemic in Havana in 2006 was contained within months — attributed to the residual effectiveness of the Cuban vector control programme. In contrast, the 1981 DENV-2 epidemic was the first time DHF/DSS appeared on a large scale in the Americas, demonstrating the classical DENV-1 primary → DENV-2 secondary ADE-enhanced severity pattern (see Guzman2016 - Dengue Infection).
Contradictions & Debates
None yet recorded.
Related Pages
- Post-Dengue Syndrome
- Autoimmunity in Dengue
- Asymptomatic Dengue Infection
- Latin America
- FcγRIIa Receptor
- PRNT
- ELISA Inhibition Method
- Antibody-Dependent Enhancement
Sources
- Garcia2009 - Long-term Clinical Symptoms Post-Dengue
- Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism
- Guzman2016 - Dengue Infection (serial serotype introduction; DENV-4 Havana 2006 containment; Cuban epidemic pattern)
- Oishi2003 - PAIgG and Thrombocytopenia in Secondary Dengue (DENV-4 antigen used in HI titer panel; secondary-infection PAIgG mechanism context)
- Palacios2016 - Autoimmunity in Dengue Literature Review (Wan2012 cross-serotype autoantibody data: similar autoantibody levels in DENV-2/3/4)
- Vo2020 - Autoantibody Profiling in Dengue (Cambodia 2012–2013; DENV-4 present in 9.09% ASD and 15.4% DF; minor serotype in this cohort)
- Dejnirattisai2010 - Anti-prM Antibodies Enhance Dengue ADE (anti-prM hmAbs from DENV-infected donors fully cross-reactive against DENV-4 antigen; complete serotype cross-reactivity of anti-prM response)
- Pang2017 - DHF Pathogenesis Review (all four DENV serotypes in ADE and T cell pathogenesis context; review, China)
- Cheng2015 - NS1 P311-330 Anti-PDI Autoantibodies in DHF (DENV-4 in 3/15 DHF patients in Vietnamese paediatric cohort; anti-endothelial autoantibody study)
- Farias2024 - Dengue Mimickers (all four serotypes noted as co-circulating in Brazil 2024 epidemic with >6M cases; background epidemiology; Brazil narrative review — secondary source)
- Hung2008 - Anti-Platelet Anti-Endothelial Autoantibodies Vietnam (DENV-4 co-circulating with DENV-2/3 in HCMC Vietnam 1998–2002; serotype-confirmed by virus isolation/RT-PCR)
- Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review (DENV-4 cited alongside DENV-2 as higher-virulence serotype citing Martina 2009; all four serotypes referenced in coagulation factor homology and autoantibody context; Kolkata India review — secondary source)